Biojector 2000: Phase I/II data

Data from a double-blind, Dominican Republican Phase I/II trial in 450 infants ages 6-24 months showed that 0.1 mL Vaxigrip influenza vaccine delivered intradermally via the Biojector 2000 needle-free injection system produced a seroconversion rate of 72% vs. 25% and 63% for 0.1 and 0.25 mL doses of the vaccine delivered intramuscularly via syringe, respectively. Seroprotection rates were 88%, 49% and 85%, respectively. The trial was conducted by the Centers for Disease Control and Prevention (CDC). Data were presented at the Vaccine Research meeting in Bethesda. ...